Company Analysis Royalty Pharma plc
1. Summary
Advantages
- Dividends (2.92%) are higher than the sector average (0.5448%).
- The stock's return over the last year (7.68%) is higher than the sector average (-37.79%).
- The company's current efficiency (ROE=17.39%) is higher than the sector average (ROE=9.48%)
Disadvantages
- Price (32.79 $) is higher than fair price (17.05 $)
- Current debt level 37.45% has increased over 5 years from 2.26%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Royalty Pharma plc | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.9% | -23.2% | 1% |
| 90 days | 30% | -36.6% | -8.6% |
| 1 year | 7.7% | -37.8% | 9.1% |
RPRX vs Sector: Royalty Pharma plc has outperformed the "Healthcare" sector by 45.47% over the past year.
RPRX vs Market: Royalty Pharma plc has underperformed the market marginally by -1.41% over the past year.
Stable price: RPRX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: RPRX with weekly volatility of 0.1478% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (32.79 $) is higher than the fair price (17.05 $).
Price is higher than fair: The current price (32.79 $) is 48% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (17.6) is lower than that of the sector as a whole (57.21).
P/E vs Market: The company's P/E (17.6) is lower than that of the market as a whole (48.7).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.63) is lower than that of the sector as a whole (4.65).
P/BV vs Market: The company's P/BV (1.63) is lower than that of the market as a whole (3.42).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (6.68) is lower than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (6.68) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (14.8) is higher than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (14.8) is lower than that of the market as a whole (25.23).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -2.38% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-2.38%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (156.84%).
5.4. ROE
ROE vs Sector: The company's ROE (17.39%) is higher than that of the sector as a whole (9.48%).
ROE vs Market: The company's ROE (17.39%) is higher than that of the market as a whole (8.97%).
5.5. ROA
ROA vs Sector: The company's ROA (6.93%) is higher than that of the sector as a whole (0.1068%).
ROA vs Market: The company's ROA (6.93%) is higher than that of the market as a whole (6.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (6.21%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (6.21%) is lower than that of the market as a whole (10.96%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 2.92% is higher than the average for the sector '0.5448%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 2.92% has been steadily paid over the past 7 years, DSI=1.
Dividend growth: Company's dividend yield 2.92% has been growing over the last 5 years. Growth over 7 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (43.77%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
